Javelin Pharmaceuticals and Baxter Healthcare have expanded their commercial supply relationship for Dyloject, Javelin’s proprietary injectable diclofenac product. The drug is currently marketed in the UK and is in Phase III trials in the U.S. for acute post-operative pain. The expanded relationship provides additional manufacturing capacity for Dyloject, principally for distribution in the EU, and builds on the existing manufacturing agreement executed between Javelin and Baxter for the United States.

"We are pleased to strengthen our relationship with Baxter. This expanded commercial supply agreement will provide increased capacity for Dyloject in Europe as we grow sales of the product in the U.K. and prepare for the anticipated launch of the product in multiple European countries in the near future.” said Martin Driscoll, Javelin's chief executive officer.

News from our sister sites